Chardan analyst Keay Nakae raised the firm’s price target on ProQR Therapeutics (PRQR) to $4 from $2.50 and keeps a Buy rating on the ...
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback